• Tumor size, grade, axillary lymph node status, steroid hormone receptor status, and human epidermal growth factor receptor 2 (HER2)/neu overexpression are the factors that most commonly influence treatment decisions and are discussed in detail below. (medscape.com)
  • Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. (thieme-connect.de)
  • Amplification of the human epidermal growth factor receptor 2 ( HER2 ) gene and overexpression of the HER2 protein is found in 15%-20% of patients with gastric and gastroesophageal junction cancer. (wjgnet.com)
  • The National Comprehensive Cancer Network (NCCN) guidelines recommend all patients newly diagnosed with breast cancer be tested for hormone receptor status via expression of estrogen and/or progesterone receptors (ER/PR) and human epidermal growth factor receptor-2 (HER2) [ 4 ]. (biomedcentral.com)
  • With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. (carcinogenesis.com)
  • One type of breast cancer is identified by the human epidermal growth factor receptor 2 (HER2) gene amplification. (carcinogenesis.com)
  • Note 1:** Record the interpretation of only the Fluorescence In Situ Hybridization (FISH) test for Human Epidermal Growth Factor Receptor 2 (HER2) in this field. (cancer.gov)
  • Determine test methodologies used to identify the expression and amplification of human epidermal growth factor receptor 2 (HER2). (labce.com)
  • Breast cancers are increasingly recognized as heterogeneous based on expression of receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2). (cdc.gov)
  • When breast cancer occurs in AYAs, it differs from that occurring in older women in several ways: a worse prognosis and more-aggressive phenotype, higher proportions of high-grade and later stage tumors, lower estrogen receptor (ER) positivity, and overexpression of human epidermal growth factor receptor 2 (HER2) [ 1 , 3 , 4 ]. (cdc.gov)
  • Human epidermal growth factor receptor 2 (HER2), a promising therapeutic target, can be mutated, amplified, or overexpressed in different malignancies, including non-small cell lung cancer (NSCLC). (biomedcentral.com)
  • Among these mutations, the gene encoding human epidermal growth factor receptor 2 (called HER2, EGFR2, NEU, or ERBB2) is a hot new therapeutic target. (biomedcentral.com)
  • Amplification of the HER2 gene and overexpression of the human epidermal growth factor receptor 2 (HER2) protein have been associated with a shorter disease-free survival and shorter overall survival in gastric and gastroesophageal junction cancers. (marshfieldlabs.org)
  • Rare cases may not show HER2 amplification but still have human epidermal growth factor receptor 2 (HER2) protein overexpression demonstrated by immunohistochemistry. (marshfieldlabs.org)
  • Patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer can benefit from trastuzumab deruxtecan. (e-crt.org)
  • Human epidermal growth factor receptor 2 (HER2) is a prognostic factor for breast cancer (BC) and a predictor of targeted therapy. (e-crt.org)
  • Objective Human epidermal growth factor receptor 2 (HER2) status identification is established by immunohi-stochemistry and in situ hybridization (ISH). (aboutscience.eu)
  • Therapy with trastuzumab confers a survival benefit in HER2 positive advanced gastric and gastroesophageal adenocarcinoma. (jcancer.org)
  • The international Trastuzumab for Gastric Cancer (ToGA) trial demonstrated that patients with human epidermal receptor 2 (HER2) overexpressing tumours benefit from targeted therapy with trastuzumab [ 1 ]. (jcancer.org)
  • And in a smaller study, the dual HER2-targeted strategy of tucatinib (Tukysa) plus trastuzumab induced responses in 46.7% (90% CI 30.8-63.0) of the 30 patients with metastatic disease, reported Yoshiaki Nakamura, MD, PhD, of the National Cancer Center Hospital Japan East in Kashiwa. (medpagetoday.com)
  • The usefulness of HER2 targeted therapy in gastric cancer was demonstrated in the ToGA trial, where HER2-positive patients with advanced gastric and gastroesophageal junction adenocarcinoma were randomized to receive 5-FU/capecitabine and cisplatin, either alone or in combination with trastuzumab. (wjgnet.com)
  • The ToGA trial must be characterized as a landmark in the treatment of gastric cancer and it has paved the way for a number of new HER2 targeted compounds such as pertuzumab, ado-trastuzumab emtansine, lapatinib, afatinib, and dacomitinib, which are currently undergoing phase II and III clinical testing. (wjgnet.com)
  • A neoadjuvant treatment regimen consisting of HER2-directed conventional dendritic cell intratumoral therapy plus paclitaxel, trastuzumab, and pertuzumab elicited pathologic complete responses in patients with stage I to III HER2-positive breast cancer. (onclive.com)
  • A neoadjuvant treatment regimen consisting of HER2-directed conventional dendritic cell (DC1) intratumoral therapy plus paclitaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta) elicited pathologic complete responses (pCRs) in patients with stage I to III HER2 positive breast cancer, according to data from the ongoing phase 2 NATASHA trial (NCT05325632) presented at the 2023 ASCO Annual Meeting. (onclive.com)
  • The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. (carcinogenesis.com)
  • We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
  • This subtype accounts for approximately 20%-30% of invasive breast cancers, and until the discovery of effective anti-HER2 therapies ( first of which is trastuzumab), was associated with reduced disease-free survival (DFS), increased risk of metastases, and shorter overall survival (OS). (carcinogenesis.com)
  • Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+. (jnccn.org)
  • Only patients who over-express HER2 (eg, positive scores by IHC, CISH, or FISH) are candidates to receive Herceptin® (trastuzumab) treatment. (labce.com)
  • Tumor Her2/ neu is generally assessed as protein overexpression by using immunohistochemistry (IHC), and patients with tumors that either have 2+ or 3+ results with this method become good candidates for treatment with trastuzumab. (biomedcentral.com)
  • Patients whose tumors demonstrate HER2 amplification or overexpression may be candidates for treatment with the drugs that target the HER2 protein or its downstream pathways (eg, trastuzumab [Herceptin], pertuzumab). (marshfieldlabs.org)
  • Although HER2-low did not affect the pCR rate and DFS, significant evolution of HER2-low expression after NACT creates opportunities for targeted therapy including trastuzumab. (e-crt.org)
  • Anti-HER2 targeted therapy drugs, represented by trastuzumab, have been shown to significantly improve the prognosis of patients with HER2-positive BC [ 2 , 3 ]. (e-crt.org)
  • The ongoing phase 1 ACE-Gastric-01 trial has shown promising anti-tumor activity in HER2-positive advanced gastric patients who have been previously treated with trastuzumab and chemotherapy in the metastatic setting," said Feng Tian, PhD, president and CEO of Ambrx, in a statement. (targetedonc.com)
  • Nondiploid tumors had a significantly greater rate of HER-2/neu amplification compared with diploid tumors (P = .0003). (nih.gov)
  • The authors conclude that HER-2/neu gene amplification status can be determined by FISH on archival prostate cancer specimens, significantly correlates with high tumor grade and nondiploid DNA content, and is more frequently encountered in tumors with advanced pathological stage. (nih.gov)
  • Results: HER2-positivity was found in up to 14.9% in our cohort (IHC score 3+ or IHC score 2+ with gene amplification) and demonstrated a significantly better overall survival (OS) in correlation to HER2-negative tumors (median OS 70.1 vs. 24.6 months, p = 0.006). (uni-frankfurt.de)
  • NATASHA is a phase 2, non-randomized, open-label study enrolling patients with HER2-positive stage I to III breast cancer whose tumors are at least 1 cm. (onclive.com)
  • Triple-negative tumors (ER - /PR - /HER2 - ) have been reported to be more common among younger women, but occurrence of the spectrum of breast cancer subtypes in adolescent and young adult (AYA) women aged between 15 and 39 years is otherwise poorly understood. (cdc.gov)
  • We recently reported in a large, population-based series from California that the hormone receptor negative, HER2 positive (HR - /HER2 + ) and triple-negative (ER negative/progesterone receptor (PR) negative/HER2 negative) tumors were more common in younger women [ 4 , 6 ]. (cdc.gov)
  • We assessed Her-2/ neu alteration using CISH on formalin-fixed paraffin-embedded primary invasive ductal carcinoma tumors in which IHC (CB11 antibody) had previously been performed, and we compared the results with IHC. (biomedcentral.com)
  • Similarly, although the small group of well-differentiated tumors was apparently Her-2/ neu negative in both tests, no significant association was noted between any tumor histologic grade and either IHC or CISH results. (biomedcentral.com)
  • The degree of HER2 amplification varies in tumors. (marshfieldlabs.org)
  • Of the 564 non-pCR patients, 57 (10.1%) changed to HER2-positive, and 64 of the 150 patients (42.7%) with HER2-0 tumors changed to HER2-low. (e-crt.org)
  • HER2-low (p=0.004) and HR-positive (p=0.010) tumors before NACT were prone to HER2 gain. (e-crt.org)
  • Previous studies have established the efficacy of novel antibody-drug conjugates (ADCs) in treating HER2-low tumors [ 7 , 8 ]. (e-crt.org)
  • In the HER2-positive tumors, ABCC3 was amplified in 16/57 tumors (28.1%, P = 0.0059). (lu.se)
  • Specifically, increased ABCC3 mRNA and gene copy numbers were most prominent in HER2 amplified and/or HER2-enriched classified tumors. (lu.se)
  • Background: HER2 (ERBB2 or HER2/neu) is a tyrosine-kinase increasing cell proliferation. (uni-frankfurt.de)
  • The HER2 amplification probe consists of a 347kb probe labelled in red, spanning the HER2 (ERBB2) gene and neighbouring regions, and a green probe for the chromosome 17 centromere. (ogt.com)
  • Also, FISH is more sensitive than IHC for detection of abnormalities in the HER-2/neu gene, and further studies should be undertaken to determine whether a FISH-based HER-2/neu detection method may prove of importance in the prediction of prognosis and planning of therapy in prostate cancer patients. (nih.gov)
  • Of 568 patients, 12% (67 patients) were HER2 + by Onco type DX and 11% (60) by FISH. (biomedcentral.com)
  • Fifty-five patients were HER2 + by both methods. (biomedcentral.com)
  • Of the 12 patients Onco type DX HER2 + but FISH negative, using FISH 11 patients were HER2 - and one patient was HER2 equivocal. (biomedcentral.com)
  • Risk of breast cancer death was significantly greater in patients with HER2 ≥ 11.5 (OR = 1.84, 95% CI = 1.13 to 2.99) compared with patients with HER2 ≤ 10.7. (biomedcentral.com)
  • CHICAGO -- In a pair of mid-stage trials, newer targeted therapies demonstrated meaningful levels of activity against HER2-positive biliary tract cancers in pretreated patients with advanced disease. (medpagetoday.com)
  • Cohort 1 of the global HERIZON-BTC-01 study, which included 80 treatment-refractory patients, showed that 41.3% (95% CI 30.4-52.8) responded to zanidatamab, an investigational bispecific monoclonal antibody that targets two distinct HER2 epitopes, according to Shubham Pant, MD, of the MD Anderson Cancer Center in Houston. (medpagetoday.com)
  • Furthermore, multiple HER2 testing modalities were shown to be reliable in identifying patients who may be eligible for this treatment regimen. (medpagetoday.com)
  • From September 2020 to March 2022, the HERIZON-BTC-01 trial enrolled 87 patients with locally advanced or metastatic HER2 -amplified biliary cancers across 32 sites in Asia, Europe, North America, and South America. (medpagetoday.com)
  • Cohort 1 included 80 patients with HER2 expression defined as an immunohistochemistry (IHC) score of 2+ or 3+, with about three-fourths having IHC 3+. (medpagetoday.com)
  • Because there are drugs that are aimed at HER2 gene amplification and overexpression, it's important to know who among patients with breast cancers has this alteration and who doesn't. (curetoday.com)
  • The HER-2/neu onkogene may play a role in the prognosis and management of patients with breast cancer. (thieme-connect.de)
  • 32 % of patients exhibited overexpression of HER-2/neu. (thieme-connect.de)
  • Patients with a strong overexpression of the HER2 protein (IHC3+) specifically benefited from the treatment, with a median overall survival of 17.9 mo. (wjgnet.com)
  • As a consequence of the positive results of the ToGA trial, patients with advanced gastric or gastroesophageal junction adenocarcinoma are now routinely tested for HER2. (wjgnet.com)
  • Regarding HER2 status, 11 patients were immunohistochemistry (IHC) 3+, and 1 patient was IHC 2+/fluorescence in situ hybridization amplified. (onclive.com)
  • Findings also showed that in patients treated with DC1 at 100 x 106 cells, there was a decrease in peripherally circulating anti-HER2 T-cell response at week 6, which study authors attributed to a likely increase in T-cell trafficking to the tumor site. (onclive.com)
  • Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA) approval in combination with capecitabine for patients with advanced HER2+ breast cancer. (carcinogenesis.com)
  • Herceptin has been successfully used in combination with other chemotherapeutic agents in breast cancer, a cancer in which only 30% of patients harbor elevated HER2/neu levels. (kanker-actueel.nl)
  • AYAs had higher proportions of HR + /HER2 + , triple-negative and HR - /HER2 + breast cancer subtypes and higher proportions of patients of non-White race/ethnicity than did older women. (cdc.gov)
  • Ten (5%) patients were diagnosed as HER2-positive because of HER2 IHC 3+, and the same 10 (5%) patients had HER2 amplification evaluated using CGS. (blogspot.com)
  • Nine of the 10 HER2-positive patients were KRAS 12/13 wild-type and were considered possible candidates for HER2-targeted therapy. (blogspot.com)
  • CGS has the same utility as IHC and FISH for detecting HER2-positive patients who are candidates for HER2-targeted therapy, and facilitates precision medicine and tailor-made treatment. (blogspot.com)
  • This study primarily assessed the prevalence of HER2 protein expression in NSCLC among Jordanian patients. (biomedcentral.com)
  • Additionally, a separate subset of patients was tested for HER2 gene mutation. (biomedcentral.com)
  • However, these patients may have a worse prognosis and be candidates for treatments that target the HER2 protein or its downstream pathways. (marshfieldlabs.org)
  • The data of HER2-negative patients receiving NACT at our center were collected. (e-crt.org)
  • Pathological complete response (pCR) rate were compared between HER2-0 and HER2-low patients. (e-crt.org)
  • The pCR rates of HER2-low and HER2-0 patients (14.2% vs. 23.0%) showed no difference in multivariate analysis regardless of HR status. (e-crt.org)
  • HER2 gain patients had a better DFS compared with HER2-negative maintained patients (87.9% vs. 79.5%, p=0.048), and the DFS of targeted therapy group was better than that of no targeted therapy group (92.4% vs. 66.7%, p=0.016). (e-crt.org)
  • More than half of HER2-negative patients have HER2-low expression [ 6 ]. (e-crt.org)
  • Discrepancies are also found in the influence of the HER2-low status on the pathological complete response (pCR) rate of patients receiving neoadjuvant chemotherapy (NACT) [ 12 , 13 , 15 ]. (e-crt.org)
  • These controversial results suggest that the clinicopathological characteristics and prognostic value of HER2-low patients with early BC receiving NACT warrant further research. (e-crt.org)
  • The FDA has granted an orphan drug designation to ARX788 for the treatment of patients with HER2-positive gastric cancer, according to a press release from developer Ambrx. (targetedonc.com)
  • ARX788 is a homogenous antibody-drug conjugate (ADC) targeting the HER2 receptor that is being investigated in a phase 1 study of patients with previously treated advanced gastric cancer. (targetedonc.com)
  • The phase 3 trial is planned to enroll patients with HER2-positive gastric or gastroesophageal junction cancer and randomize them to receive either ARX788 or physician's choice of therapy in the second-line setting. (targetedonc.com)
  • The ADC is being investigated in an ongoing dose-escalation phase 1 study (NCT03255070) in patients with advanced cancers with HER2 expression. (targetedonc.com)
  • ARX788 has already demonstrated promise in the breast cancer setting and was granted an FDA fast track designation earlier in the year for the treatment of patients with advanced or metastatic HER2-positive breast cancer who have received at least 1 prior anti-HER2 regimen in the metastatic setting. (targetedonc.com)
  • This study sought to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of eribulin in combination with durvalumab, as well as the safety and preliminary antitumor activity of the combination in patients with previously treated HER2-negative (HER2-) MBC and recurrent ovarian cancer (ROC). (bvsalud.org)
  • METHODS: Cohorts of 3-6 patients with HER2- MBC and ROC were treated in a modified 3+3 design. (bvsalud.org)
  • RESULTS: Nine patients with a median of 4 prior therapies for advanced disease were treated: 5 patients with HER2- MBC (1 with triple negative disease and 4 with hormone positive disease) and 4 patients with ROC. (bvsalud.org)
  • CONCLUSION: The combination of eribulin at a dose of 1.4 mg/m2 with standard dose durvalumab had a favorable AE profile in patients with previously treated HER2- MBC and ROC. (bvsalud.org)
  • The results were compared with HER-2/neu protein expression as determined by IHC and correlated by logistic regression analysis with Gleason tumor grade, DNA ploidy, serum prostate specific antigen (PSA), and pathological stage. (nih.gov)
  • What is HER2 tumor marker testing? (medlineplus.gov)
  • HER2 is a type of tumor marker. (medlineplus.gov)
  • So, HER2 tumor marker testing is necessary to find out if targeted therapy will be helpful. (medlineplus.gov)
  • There are different HER2 tumor marker tests for checking HER2 proteins and HER2 genes. (medlineplus.gov)
  • HER2 tumor marker tests are mostly used to find out whether certain cancers are HER2 positive or negative. (medlineplus.gov)
  • Why do I need HER2 tumor marker testing? (medlineplus.gov)
  • The cancer growing outside of your breast should be tested to see if it's HER2 positive, even if your breast tumor was already tested. (medlineplus.gov)
  • The new tumor should be tested to see if it's HER2 positive even if your first tumor was tested. (medlineplus.gov)
  • What happens during a HER2 tumor marker test? (medlineplus.gov)
  • Most HER2 testing uses a sample of tumor tissue. (medlineplus.gov)
  • Central confirmation of HER2 amplification was required by fluorescence in-situ hybridisation (FISH), and testing was only allowed on tumor tissue. (medpagetoday.com)
  • This means that the cancer cells have increased the number of copies of the HER2 gene in each tumor cell. (curetoday.com)
  • Whereas normal cells have two copies of the HER2 gene, cancer cells often have greater than 20 copies per tumor cell. (curetoday.com)
  • T-DM1), which is linked to a biological toxin, so that the drug is directed to tumor cells that overexpress HER2. (curetoday.com)
  • Either one of these classes of drugs prevent the continuous stimulation of HER2 in tumor cells. (curetoday.com)
  • The current ASCO-CAP guidelines for HER2 testing by FISH require consideration of both the HER2 -to-CEP17 ratio and the average HER2 gene copy number per tumor cell. (curetoday.com)
  • We performed HER2 immunohistochemistry (IHC) according to the guidelines and fluorescence-in-situ-hybridization (FISH) for IHC score2+, using tissue micro arrays (TMA) with up to eight biopsies from the surface and infiltration area of a single tumor for evaluating HER2-heterogeneity and single-spot TMA. (uni-frankfurt.de)
  • HER2-overexpression was more frequently seen in lower tumor stages (pT1/pT2, p = 0.038), in the absence of lymphatic metastases (pN0/pN+, p = 0.020), and was significantly associated with better histological grading (G1/G2) (p = 0.041). (uni-frankfurt.de)
  • Preclinical and clinical studies have demonstrated that the vaccine led to primary tumor control and a decrease in anti-HER2 CD4 Th1 in peripheral blood. (onclive.com)
  • Tumor cell resistance to taxanes is at least in part mediated by the HER2/NEU oncogene. (kanker-actueel.nl)
  • We have previously characterized HER2/NEU expression in human pancreatic cancer cell lines and studied the anti-tumor activity of Herceptin monotherapy in vitro and in vivo. (kanker-actueel.nl)
  • This requires the application to a tumor tissue sample of fluorescent probes that attach themselves to the HER-2 genes in a process called hybridization. (unifi.it)
  • We also compared age at diagnosis and tumor histologic grade with IHC and CISH Her-2/ neu . (biomedcentral.com)
  • Her-2/ neu testing should be done on all breast cancer cases regardless of age at presentation and tumor histologic grade. (biomedcentral.com)
  • The prognostic information provided by the HER2 status of a patient's tumor should not be interpreted in isolation because other prognostic features (eg, lymph node status, tumor size) may be of equal or greater importance in determining the patient's prognosis. (marshfieldlabs.org)
  • Given the unclear prognostic characteristics of HER2-low breast cancer, we investigated the prognostic characteristics of HER2-low expression from primary tumor to residual disease after neoadjuvant chemotherapy (NACT). (e-crt.org)
  • The evolution of HER2 expression from primary tumor to residual disease and its impact on disease-free survival (DFS) were examined. (e-crt.org)
  • Traditional methods for tumor characterization are tumor-type specific and include assays such as immunohistochemistry (IHC), in situ hybridization (ISH), quantitative PCR (qPCR), Sanger sequencing and gene signature microarrays [ 1 - 8 ]. (oncotarget.com)
  • Fluorescence and chromogenic in situ hybridization, using an ABCC3-specific probe, was used to analyze 11 breast cancer cell lines and 112 clinical tumor samples. (lu.se)
  • HER2-targeted therapy is considered effective for KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (CRC). (blogspot.com)
  • HER2 genes have instructions for making the HER2 protein. (medlineplus.gov)
  • Normally, you have two HER2 genes in each cell, one from each parent. (medlineplus.gov)
  • HER2 positive , which means the cancer has high levels of the HER2 protein or HER2 genes. (medlineplus.gov)
  • HER2 negative , which means your cancer cells have little to no HER2 protein or a normal number of HER2 genes. (medlineplus.gov)
  • We also performed an MLPA HER2 assay that evaluates 22 genes on chromosome 17. (jcancer.org)
  • CGS successfully detected alterations in 415 genes including KRAS codon 12/13 mutation and HER2 amplification. (blogspot.com)
  • There are conflicting data concerning the impact of HER2 overexpression on esophageal adenocarcinoma (EAC), as most studies do not differ between cancers of the esophagus/gastroesophageal junction and the stomach. (uni-frankfurt.de)
  • Overall, this review will discuss the current status of HER2 in gastric and gastroesophageal junction cancer and the future direction in relation to HER2 target therapy. (wjgnet.com)
  • HER-2/neu expression has been established as a prognostic factor in breast and other cancers. (nih.gov)
  • Some types of cancer cells make larger than normal amounts of HER2, including certain cancers of the breast , stomach , and esophagus . (medlineplus.gov)
  • Cancers with large amounts of HER2 protein tend to grow quickly and spread to other parts of the body. (medlineplus.gov)
  • Certain medicines, called HER2 targeted therapy, can block or slow HER2 proteins and help control these cancers. (medlineplus.gov)
  • But these medicines won't help cancers that don't have high levels of HER2 proteins. (medlineplus.gov)
  • But certain cancers have extra copies of the HER2 gene, which leads to too much HER2 protein on the cancer cells. (medlineplus.gov)
  • These cancers are likely to respond to HER2 targeted therapy. (medlineplus.gov)
  • Cancer of the pancreas, bladder, ovaries , or certain other cancers that may have high levels of HER2 which may be treated with medicines that target HER2. (medlineplus.gov)
  • Furthermore, he said, not all types of biliary cancers express HER2 the same way. (medpagetoday.com)
  • Approximately 20 percent to 25 percent of breast cancers in women have the HER2 gene alteration, also known as gene amplification. (curetoday.com)
  • In the past, women were enrolled in clinical trials of HER2-targeted drugs if they had HER2-positive breast cancers. (curetoday.com)
  • When the ratio of the HER2 gene compared with the centromere (CEP17) is greater than 2, these breast cancers are referred to as HER2 -amplified. (curetoday.com)
  • Around 10% of all breast cancers are hormone receptor-positive and HER2-positive. (medicalnewstoday.com)
  • Immunohistochemistry was performed using antibodies to phospho-AMPK (pAMPK), phospho-Acetyl Co-A Carboxylase (pACC) an established target for AMPK, HER2, ERα, and Ki67 on Tissue Micro-Array (TMA) slides of two cohorts of 117 and 237 primary breast cancers. (biomedcentral.com)
  • Data regarding all 5,605 AYA breast cancers diagnosed in California during the period 2005 to 2009, including ER and PR status (referred to jointly as hormone receptor (HR) status) and HER2 status, was obtained from the population-based California Cancer Registry. (cdc.gov)
  • Therefore, the better to understand the occurrence of AYA breast cancer subtypes, we took advantage of HER2 data recently available for breast cancers occurring in the large and diverse California population from 2005 to 2009. (cdc.gov)
  • In much the same way as was demonstrated for HER2 -positive breast cancer, the HER2 gene status in gastroesophageal cancers can be used to determine treatment approaches. (marshfieldlabs.org)
  • Receiving orphan drug designation from the FDA is an important milestone in our ongoing efforts to develop ARX788 for a wide range of HER2-positive cancers. (targetedonc.com)
  • ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers. (targetedonc.com)
  • A trend for similar HER-2/neu status in each PC by the two methods did not reach statistical significance (P = .23). (nih.gov)
  • Advances in fluorescence microscopy, fluorescent dyes, biotechnology, bioinformatics, and research on the human genome project in the late 90's accelerated the development of methods to synthesize and design NA probes for FISH. (springer.com)
  • Until recently, real-time quantitative PCR (qPCR) assays and microarray hybridization have been the main methods used to determine copy number variation (CNV) in the genome. (bio-rad.com)
  • The primary aim of this analysis is to evaluate the economical and organizational impact of adopting FISH or SISH methods for HER2 testing. (aboutscience.eu)
  • What is controversial about the HER2 oncogene right now in breast cancer? (curetoday.com)
  • The HER2/neu oncogene is overexpressed in up to 70% of human pancreatic cancer specimens when compared to normal pancreatic tissue. (kanker-actueel.nl)
  • The Her-2/ neu proto-oncogene, also known as c-erbB-2, is a member of the type I growth factor receptor gene family and is located in the long arm of chromosome 17 (17q12-21.32) [ 1 ]. (biomedcentral.com)
  • HER2 is a glycoprotein encoded by the HER2 gene, a proto-oncogene found on the long arm of chromosome 17. (biomedcentral.com)
  • Recent studies suggest that the HER2 oncogene can be used as a marker to identify aggressive disease. (marshfieldlabs.org)
  • The authors studied DNA amplification of the HER-2/neu gene on 4-microm sections obtained from 62 formalin-fixed, paraffin-embedded PCs by fluorescence in situ hybridization (FISH). (nih.gov)
  • There was no correlation of HER-2/neu amplification by FISH with patient age or preoperative serum PSA levels. (nih.gov)
  • In this analysis, HER2 results obtained with Onco type DX, a validated 21-gene recurrence score assay utilizing RT-PCR, were compared with standard fluorescence in situ hybridization (FISH) results. (biomedcentral.com)
  • There is a high degree of concordance between RT-PCR using Onco type DX and central laboratory FISH assessment of HER2 status. (biomedcentral.com)
  • Fluorescence in situ hybridization (FISH) is a molecular cytogenetic technique that uses fluorescent probes that bind to only particular parts of a nucleic acid sequence with a high degree of sequence complementarity. (wikipedia.org)
  • To develop and evaluate an automated method for quantification of HER2 fluorescence in situ hybridisation (FISH) signals. (bmj.com)
  • The FISH quantification tool (FishJ) is available for download as an ImageJ macro or alternatively it can be utilised through a web interface with an option of uploading FISH images for hybridisation signal counting. (bmj.com)
  • The continuous flow of probes and shaping liquid on these selected cells resulted in a 120-fold reduction of the hybridization time compared with the standard protocol (3 min vs. 6 h) and efficient rinsing, thereby shortening the total FISH assay time for centromeric probes. (springer.com)
  • A key milestone in ISH-based techniques was fluorescence in situ hybridization (FISH) (Bauman et al. (springer.com)
  • He has recommended changes to updated ASCO-CAP guidelines on assessment of HER2 amplification by fluorescence in situ hybridization (FISH). (curetoday.com)
  • Press, the Harold E. Lee Chair for Cancer Research in the Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California, discussed the new ASCO-CAP guidelines for HER2 FISH testing at the 2017 Miami Breast Cancer Conference. (curetoday.com)
  • On the other hand, the ASCO-CAP guidelines committee did make a number of changes in the way the HER2 gene is evaluated by FISH for gene amplification. (curetoday.com)
  • These changes have created confusion about whether or not some FISH subgroups are HER2 amplified, known as in situ hybridization (ISH)-positive, or HER2 not amplified, known as ISH-negative. (curetoday.com)
  • The ASCO-CAP guidelines for HER2 testing by FISH have created new definitions of what is HER2-positive and what is HER2-negative. (curetoday.com)
  • The definition of HER2-positive by FISH in the past referred to a ratio between the number of copies of the HER2 gene, compared with a control gene on the same chromosome arm that was greater than 2. (curetoday.com)
  • Fluorescence in situ hybridization (FISH) is a cytogenetic technique used to detect and localize the presence or absence of specific DNA sequences on chromosomes. (unifi.it)
  • A doctor may also use a fluorescence in situ hybridization (FISH) test to check HER2 levels in cancer cells. (medicalnewstoday.com)
  • A FISH test uses specialized fluorescent dye and DNA to show changes in chromosomes and can also show levels of the HER2 gene. (medicalnewstoday.com)
  • Highly specific CytoCell ® FISH probes are capable of detecting genetic changes in a variety of sample types, in situ . (ogt.com)
  • The FAST FISH Prenatal kit allows detection of trisomies 13, 18 and 21 (Patau, Edwards and Down syndromes) and sex chromosome aneuploidies utilising a 2 hour hybridisation protocol. (ogt.com)
  • Fluorescence in situ hybridization (FISH) is a molecular pathological method with high sensitivity and specificity, which uses specific DNA probes to detect chromosomal aberrations, as well as gene deletion and amplification ( 21 , 22 ). (spandidos-publications.com)
  • Her-2/ neu gene amplification is primarily detected by in situ hybridization and uses fluorescence (FISH) to detect the signals. (biomedcentral.com)
  • Chromogenic in situ hybridization (CISH) is a recently introduced method, and although it makes use of the in situ hybridization technology of FISH, it also takes advantage of the chromogenic signal detection of IHC that can be detected with the ordinary light microscope and costs one-quarter as much as FISH. (biomedcentral.com)
  • In general, HER2 status is determined by the use of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). (blogspot.com)
  • The HER2 status of the primary site was assessed using IHC and FISH, and HER2 amplification of the primary site was also assessed using CGS, and the findings of these approaches were compared in each patient. (blogspot.com)
  • The HER2 FISH test is not approved by the FDA for this indication and should be used as an adjunct to existing clinical and pathologic information. (marshfieldlabs.org)
  • In the study, HER2 expression is being determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) testing. (targetedonc.com)
  • Silver in situ hybridization (SISH) is an alternative technique to the fluorescence in situ hybridization (FISH). (aboutscience.eu)
  • Conclusions As highlighted by the significant reduction of laboratory staff working hours, medical resources used and pathology laboratory spaces, the use of SISH technique to identify HER2 status is a cost-saving alternative to FISH from the perspective of the pathology laboratory. (aboutscience.eu)
  • HER2 is a member of the cErbB family of receptor tyrosine kinases, and is responsible for HER2-mediated signal transduction in the cytoplasm. (carcinogenesis.com)
  • Omdat bij 70% van de alvleesklierkankerpatiënten de HER2-Neu expressie oververtegenwoordigd is en juist Herceptin bij borstkankerpatiënten met deze receptor uitstekende resultaten laat zien zijn deze trials opgezet. (kanker-actueel.nl)
  • 3 Baselga J, Norton L, Albanell J, Kim Y M, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. (thieme-connect.de)
  • Ook omdat halverwege de studie nog weinig patiënten in leven waren en een minderheid van de patiënten de juiste mutatie hadden, slechts 11% (van ruim 200 deelnemende patienten) toonde een vorm van expressie geschikt voor herceptin. (kanker-actueel.nl)
  • Her2-neu expressie is bepalend of een kankerpatiënt in aanmerking komt voor herceptin of niet. (kanker-actueel.nl)
  • Duitse onderzoekers publiceren in oktober a.s. het abstract van een aantal laboratoriumstudies en dierstudies die ze gedaan hebben met Herceptin als basis aangevuld met gemcitabine en/of docetaxel bij inoperabele en gevorderde alvleesklierkanker . (kanker-actueel.nl)
  • The tumour specimens were hybridised with probes for HER2 and chromosome 17 centromere (CEP17) and selected areas were digitised for image processing. (bmj.com)
  • The clinical benefit demonstrated by those drugs in advanced disease has triggered several adjuvant and neoadjuvant trials testing them in combination with chemotherapy, but also without conventional chemotherapy, using single or dual HER2-targeting drugs. (carcinogenesis.com)
  • Seven of the 10 cases had been assigned to receive L. Cases and controls were comparable with respect to menopausal and nodal status, local and chemotherapy, and HER2 positivity. (biomedcentral.com)
  • Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes. (wikipedia.org)
  • Through multi-band fluorescence microscopy the positions where the fluorescent probes bound to the chromosomes can be displayed so as to derive information of clinical relevance based on the presence and position of the fluorescent probes. (unifi.it)
  • It relies on the sequence-specific hybridization of probes to their complementary targets in individual cells, followed by direct or indirect detection of the labelled probe. (springer.com)
  • Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes. (cdc.gov)
  • The Onco type DX HER2 results were then associated with relative risk of breast cancer death. (biomedcentral.com)
  • Logistic regression was used to estimate association between Onco type DX HER2 results and risk of breast cancer death. (biomedcentral.com)
  • Although the updates have resulted in no changes for approximately 90 percent to 95 percent of cases, they will result in potential disagreements for approximately 5 percent of HER2 breast cancer cases, according to Press. (curetoday.com)
  • Consequently, HER2 targeting is established in breast and upper gastrointestinal tract cancer. (uni-frankfurt.de)
  • Conclusion: We demonstrated a positive prognostic impact of HER2 overexpression in a large cohort of EAC, contrary to other solid malignancies including gastric cancer and breast cancer, but consistent to the results of a large study on EAC from 2012. (uni-frankfurt.de)
  • HER-2/neu amplification predicts poor survival in node-positive breast cancer. (thieme-connect.de)
  • Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. (thieme-connect.de)
  • Few studies have evaluated survival, treatment, resource use, and costs among women with stage IV ER + breast cancer (BC) who did not receive HER2 targeted therapy. (biomedcentral.com)
  • We found significant excess clinical and economic burden among women with stage IV ER + breast cancer who did not receive HER2 targeted therapy. (biomedcentral.com)
  • In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. (carcinogenesis.com)
  • Triple-positive breast cancer is a type of breast cancer that tests positive for estrogen receptors, progesterone receptors, and high levels of HER2 protein. (medicalnewstoday.com)
  • Some types of breast cancer cells use estrogen and progesterone as well as a protein called HER2 to grow. (medicalnewstoday.com)
  • These features mean that treating triple-positive breast cancer can involve using hormone therapy and drugs to target hormone receptors and HER2. (medicalnewstoday.com)
  • HER2 is a protein that allows breast cancer cells to grow quickly . (medicalnewstoday.com)
  • If breast cancer has a higher amount of HER2 than usual, the breast cancer is HER2-positive. (medicalnewstoday.com)
  • To diagnose triple-positive breast cancer, doctors will test a biopsy sample for hormone receptors and HER2 levels. (medicalnewstoday.com)
  • According to a 2018 article , treating triple-positive breast cancer may include using hormone therapy to target hormone receptors, either on its own or alongside drugs to target HER2. (medicalnewstoday.com)
  • HER2 over-expression in breast cancer is localized to chromosome 17. (labce.com)
  • We report a case of ductal carcinoma diagnosed within a squamous epithelial inclusion cyst within an axillary lymph node in a patient with pure ductal carcinoma in situ (DCIS) of the ipsilateral right breast. (hindawi.com)
  • In 20-30% of breast carcinomas, Her-2/ neu status is altered, and this is manifested either as amplification of the gene or overexpression of the protein product [ 3 ]. (biomedcentral.com)
  • We conclude that ABCC3 is frequently amplified and overexpressed in HER2-positive breast cancer, and something that warrants further studies correlating the results with therapeutic outcome. (lu.se)
  • The good news is that there are several different HER2-targeted therapies that interfere with the actions of the overexpressed protein on the cell surface. (curetoday.com)
  • DNA microarrays using comparative genomic hybridization (CGH) are frequently used for CNV screening. (bio-rad.com)
  • CIENCIASMEDICASNEWS: Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. (blogspot.com)
  • Reports also interpret the HER2 copy number changes relative to chromosome 17 copy number (aneusomy) or potential structural genomic abnormalities that increase HER2 copy number. (marshfieldlabs.org)
  • Another class of agents is anti-HER2 small molecule inhibitors. (curetoday.com)
  • The degree of HER2 overexpression and amplification varies with the location of the carcinoma, with higher expression in the gastroesophageal and proximal parts compared to the distal parts of the stomach. (wjgnet.com)
  • The HER-2/neu gene was localized using the Oncor (Gaithersburg, MD) digoxigenin-labeled unique sequence probe. (nih.gov)
  • The hybridization signals for each probe when a nucleic abnormality is detected. (wikipedia.org)
  • After checking all the necessary conditions, hybridization steps can be started by first adding a target-specific probe, composed of 20 oligonucleotide pairs, hybridizes to the target RNA(s). (wikipedia.org)
  • MLPA can detect HER2 amplification missed by IHC and ISH, and thus may be an effective ancillary technique in evaluating HER2 status. (jcancer.org)
  • This has resulted in the routine evaluation of HER2 status in gastric and GEJ adenocarcinomas by immunohistochemistry (IHC) and in situ hybridization (ISH) [ 1 - 3 ]. (jcancer.org)
  • The HER2-status was correlated with clinicopathological data. (uni-frankfurt.de)
  • No association was observed between DFS and HER2 status. (e-crt.org)
  • The diverse evolution of HER2 status before and after NACT have been observed in previous studies [ 16 - 18 ]. (e-crt.org)
  • The results of ABCC3 were correlated with the amplification status of HER2 and topoisomerase II alpha (TOP2A), which are located close to ABCC3 at 17q12-q21. (lu.se)
  • Due to our study's relatively small sample size, a larger one is required to investigate the prognostic value and the molecular associations between the different Her2 alterations. (biomedcentral.com)
  • The process is done in 3 main procedures: tissue preparation (pre-hybridization), hybridization, and washing (post-hybridization). (wikipedia.org)
  • The aim of this study was to analyze the expression/amplification of HER2 in EAC in correlation to clinicopathological data to verify its prognostic impact. (uni-frankfurt.de)
  • In addition, the possible association between HER2 protein expression and clinicopathological variables was evaluated. (biomedcentral.com)
  • HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay (see sections 4.4 and 5.1). (who.int)
  • Although we noted Her-2/ neu positivity more in premenopausal women, the age at diagnosis was not significantly associated with IHC or CISH results. (biomedcentral.com)
  • CISH is potentially able to detect Her-2/ neu gene amplification and to minimize, if not eliminate, the false positive fraction with the IHC procedure. (biomedcentral.com)
  • According to previous studies, the prognostic value of HER2-low remains controversial [ 12 - 14 ]. (e-crt.org)
  • But right now what I can say is that every patient that we have with advanced biliary cancer, whose treatment is planned, should be tested for HER2 expression and probably for HER2 mutations as well. (medpagetoday.com)
  • This finding could indicate that HER-2/neu expression is a new independent prognostic factor. (thieme-connect.de)
  • Examine current test methodologies used to identify the expression and amplification of HER2. (labce.com)
  • No significant association was found between pAMPK and any of HER2, ERα, or Ki67 expression, disease-free survival or overall survival. (biomedcentral.com)
  • A total of 100 surgically resected NSCLC cases treated at King Hussein Cancer Center (KHCC) between 2009 and 2021 were examined for HER2 protein expression using immunohistochemistry (IHC). (biomedcentral.com)
  • At present, BC is categorized into HER2-positive (20%) and HER2-negative (80%) according to HER2 expression [ 1 ]. (e-crt.org)
  • HER2-0 expression is defined as IHC 0. (e-crt.org)
  • The agent also outperformed T-DM1 in xenograft models with both high and low HER2 expression. (targetedonc.com)
  • This type of cancer may grow more slowly than HER2-positive cancer. (medlineplus.gov)
  • Ko cautioned, however, that each trial had differences in eligibility criteria and definitions for HER2-positive disease, with activating HER2 mutations (often not associated with overexpression) used for eligibility in some tyrosine kinase inhibitor trials. (medpagetoday.com)
  • The fluorescence in each droplet is measured, and those above a threshold are counted as positive, thus providing a digital (yes/no) result. (bio-rad.com)
  • Nevertheless, a negative (0 or 1+) or a 3+ Her-2/ neu IHC correlates well with a negative or positive Her-2/ neu gene amplification, respectively. (biomedcentral.com)
  • however, little is known about the utility of CGS for detecting HER2-positive CRC. (blogspot.com)
  • The DESTINY-Breast04 phase 3 trial recently reported positive results for HER2-low advanced BC [ 9 ]. (e-crt.org)
  • Of the cell lines studied 6 HER2-positive lines and 1 HER2-negative line exhibited amplification of ABCC3. (lu.se)
  • The correlation coefficient between the automatic and manual HER2 /CEP17 ratios was 0.98. (bmj.com)
  • Silver ISH for HER2 and CEP17 were performed and scored by manufacturer guidelines. (jcancer.org)
  • The use of ratios in HER2 ISH assumes that CEP17 accurately represents chromosome 17 copy number [ 2 , 3 , 5 ]. (jcancer.org)
  • Guidelines mandate demonstration of 95% concordance to another laboratory or method before reporting patient HER2 results. (biomedcentral.com)
  • This study shows that it is possible to automate the determination of HER2 amplification by the use of open-source software, with results comparable to manual counting. (bmj.com)
  • Using linked Surveillance, Epidemiology, and End Results (SEER) and Medicare data from 2006-2009, women aged 66+ years with an incident diagnosis of stage IV ER + BC (index date) in 2007 and no HER2 targeted therapy were identified. (biomedcentral.com)
  • Knowing whether cancer cells have estrogen or progesterone receptors, and the level of HER2 protein, can help determine the best course of treatment. (medicalnewstoday.com)
  • Fisher's exact test was used to assess the association between HER2 scores and the other variables. (biomedcentral.com)